A Secondary Checkpoint Refines CRISPR Precision
CMN Briefs
Apr. 19, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
bluebird bio
Main focus: Gene therapies and gene editing for the treatment of genetic diseases
Company stage: Clinical
Diseases (gene editing): Haemophilia and other severe genetic diseases
Genome editing tool: megaTAL
Funding stage: Public
Location: Cambridge, MA, USA
Website: https://www.bluebirdbio.com/
Pipeline: https://www.bluebirdbio.com/our-science/pipeline
Gene editing partnerships: Novo Nordisk
bluebird bio develops novel gene and cancer therapies. The company is developing its proprietary megaTAL gene-editing technology, although it still has to disclose its first pre-clinical candidate derived from this. The company has a collaboration with Novo Nordisk to jointly develop next generation in vivo genome-editing treatments for genetic diseases, including haemophilia.
